CSL Behring announced the FDA approved a 50mL/10gm prefilled syringe for Hizentra, Immune Globulin Subcutaneous 20% Liquid. Hizentra is the first and only immune globulin available in a ready-to-use prefilled syringe. The 50mL prefilled syringe will be available in early 2024, which will allow CSL Behring to manufacture supply to meet anticipated demand. Hizentra will continue to be available in 5mL, 10mL and 20mL prefilled syringes as well as in 5mL, 10mL, 20mL, and 50mL vials.
Published first on TheFly
